Jean-Claude Maurel

About Jean-Claude Maurel

Jean-Claude Maurel is the founder of Medesis Pharma and currently serves as Chairman of the management board and Chief Executive Officer. He is a key figure in the governance of this French biopharmaceutical company, and his career has been built around pharmaceutical research, development, and the commercialization of innovative drug products. Medesis Pharma presents him as having more than 30 years of experience in R&D and in bringing novel pharmaceutical solutions to market. Before founding Medesis Pharma, Jean-Claude Maurel created Natura Medica in 1985, a company focused on the commercialization of natural-product assets. That company was later acquired in 1990 by Ipsen-Beaufour. In 1991, he established a research company that, after roughly ten years of chemical and pharmacological exploration, identified the lipid constituents that became the scientific basis of the Aonys® technology, now at the center of Medesis Pharma’s platform. Medesis Pharma itself was created in 2003 by consolidating earlier patents and accumulated know-how under his leadership. As CEO, Maurel has steered Medesis Pharma toward the development of oral drug-delivery solutions for therapeutic molecules, with a particular focus on serious diseases and indications where effective treatments remain limited or unavailable. His strategic approach combines scientific innovation, patent-backed intellectual property, and clinical development. The company has advanced programs built around candidates such as NanoLithium, aimed at neurological and metabolic indications, while also pursuing industrial partnerships to accelerate development. His leadership profile is notable for blending scientific entrepreneurship with long-term platform building. Rather than simply managing a company, Maurel has acted as a founder-innovator, shaping a differentiated biotechnology business centered on a proprietary delivery technology. His career reflects sustained commitment to translational research, the creation of defensible pharmaceutical assets, and the development of therapies intended to address unmet medical needs.